NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China

Distribution agreement signed between the companies for the marketing of lercanidipine tablets in China

 
Distribution agreement signed between the companies for the marketing of lercanidipine tablets in China Lee Pharmaceutical Holdings Limited (Website: www.leespharm.com) today announced in conjunction with Recordati S.p.A. ( Website www.recordati.com), a European pharmaceutical group, the execution of a License and Supply Agreement for Recordati\'s original product ZanidipĀ® (lercanidipine) in China. The agreement grants Leespharm an exclusive license to market and sell ZanidipĀ® (lercanidipine tablets) for the treatment of hypertension in the People\'s Republic of China. \"We are delighted to enter into this partnership with Leespharm for ZanidipĀ®. This represents a new step in our international partnering strategy\" said Giovanni Recordati, Chairman and CEO of Recordati. \"Leespharm is a highly capable development and commercial organization in China and we look forward to working with Leespharm toward the common goal of enriching the distribution network in Asia for ZanidipĀ® for the benefit of patients with hypertension.\" \"We are excited to announce this partnership with Recordati for ZanidipĀ®. In the light of increasing prevalence of hypertension among Chinese, the favorable efficacy and safety profile of lercanidipine could be a preferable choice for antihypertensive treatment across a broad range of patients,\" stated Dr. Benjamin Li, the Chief Executive Officer of Leespharm. \"China reports more than 200 million patients suffering from hypertension, it is expected that there will be an acceleration of penetration of ZanidipĀ® in China market in the near future.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.